

Pacritinib

Catalog No: tcsc1741



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

937272-79-2

Formula:

$C_{28}H_{32}N_4O_3$

Pathway:

Protein Tyrosine Kinase/RTK;Epigenetics;Stem Cell/Wnt;JAK/STAT Signaling

Target:

FLT3;JAK;JAK;JAK

Purity / Grade:

>98%

Solubility:

DMSO : 5.4 mg/mL (11.43 mM; Need ultrasonic and warming)

Alternative Names:

SB1518

Observed Molecular Weight:

472.58


Product Description

Pacritinib is a potent inhibitor of both wild-type **JAK2** (IC_{50} =23 nM) and **JAK2^{V617F}** mutant (IC_{50} =19 nM). Pacritinib also inhibits **FLT3** (IC_{50} =22 nM) and its mutant **FLT3^{D835Y}** (IC_{50} =6 nM).

IC50 & Target: IC_{50} : 6 nM (FLT3^{D835Y}), 22 nM (FLT3^{wt}), 19 nM (JAK2^{V617F}), 23 nM (JAK2^{wt})^[1]

In Vitro: Relative to JAK2, Pacritinib (SB1518) is two-fold less potent against TYK2 (IC_{50} =50 nM), 23-fold less potent against JAK3 (IC_{50} =520 nM) and 56-fold less potent against JAK1 (IC_{50} =1280 nM). The rest of the evaluated kinases show m). Pacritinib inhibits MV4-11 and MOLM-13 cells (both of which are cell lines derived from human acute myeloid leukemias driven by an FLT3 ITD mutation) with IC_{50} of 47 and 67 nM, respectively. Pacritinib inhibits Karpas 1106P and Ba/F3-JAK2^{V617F} cells (which are cell lines dependent on JAK2 signaling) with IC_{50} of 348 and 160 nM, respectively^[1]. FLT3-ITD harboring MV4-11 cells are treated for 3 h with different concentrations of Pacritinib (SB1518) and pFLT3, pSTAT5 and pERK1/2 levels are quantified. Pacritinib leads to a dose-dependent decrease of pFLT3, pSTAT5, pERK1/2 and pAkt with IC_{50} of 80, 40, 33 and 29 nM, respectively. The IC_{50} on auto-phosphorylation of FLT3-wt in RS4;11 is four-fold higher (IC_{50} =600 nM) compare with FLT3-ITD in MV4-11 and MOLM-13 cells. However, STAT5 inhibition is detected at much lower concentrations of Pacritinib (IC_{50} =8 nM)^[2].

In Vivo: For evaluation of efficacy in the Ba/F3-JAK2^{V617F} engraftment model, mice are treated with Pacritinib (SB1518) at doses of 50 or 150 mg/kg p.o. q.d. for 13 days, with drug dosing starting 4 days after cell inoculation. At study termination, the vehicle control mice exhibit splenomegaly and hepatomegaly (~7- and 1.3-fold, respectively), reminiscent of the symptoms found in patients with symptomatic myelofibrosis. SB1518 treatment at 150 mg/kg p.o. q.d. significantly ameliorates all these symptoms, with 60% (\pm 9%) normalization of spleen weight and 92% (\pm 5%) normalization of liver weight and is well tolerated without significant weight loss or any hematological toxicities, including thrombocytopenia and anemia^[1]. In rats, Pacritinib (SB1518) shows moderately fast absorption (t_{max} =4 h), with a peak concentration of 114 ng/mL, AUC of 599 ng•h/mL, and a terminal half-life of ~6 h following a single oral dose of 10 mg/kg. In dogs, Pacritinib (SB1518) is rapidly absorbed (t_{max} =2.0 h), with a peak concentration of ~12 ng/mL, AUC of 53 ng•h/mL, and a terminal half-life of 3.4 h following a single oral dose of 3 mg/kg^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!